<DOC>
	<DOCNO>NCT00285597</DOCNO>
	<brief_summary>This double-blind , placebo-controlled , cross-over study evaluate effect UDCA peripheral blood flow immune function patient stable chronic heart failure ( CHF ) . Sixteen patient CHF recruit heart failure clinic Royal Brompton Hospital . Following baseline evaluation , patient randomise receive either placebo UDCA dose 1000 mg/day period four week . They undergo repeat evaluation ( peripheral blood flow immune function ) . A four week washout period take place patient cross-over receive respective therapy four week ( i.e . first receive placebo go onto receive UDCA vice versa ) . The study complete total twelve week , final assessment ( peripheral blood flow immune function ) .</brief_summary>
	<brief_title>Ursodeoxycholic Acid Chronic Heart Failure</brief_title>
	<detailed_description />
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Ursodeoxycholic Acid</mesh_term>
	<criteria>age &gt; 21 year either sex patient willing capable complying requirement protocol patient provide write informed consent patient clinical evidence chronic heart failure : reduce ejection fraction ( ≤40 % ) leave ventricular impairment echocardiography ( LVEDD ≥60mm ) stable clinical condition medication least 1 month prior study ( New York Heart Association class IIIV ) . patient receive appropriate conventional medical therapy heart failure ( ACE inhibitor angiotensin II blocker , diuretic , betablocker indicate tolerate ) . congenital heart disease lifethreatening disease , heart failure active malignancy type , history malignancy within previous 5 year . Patients history malignancy surgically remove evidence recurrence least five year prior study enrolment acceptable . previous heart transplant severe neuromuscular disease history unstable angina , myocardial infarction stroke within 3 month prior study pregnancy woman childbearing age treatment immunosuppressive therapy e.g . steroid rheumatoid arthritis obstructive lung disease significant renal dysfunction ( serum creatinine &gt; 250mmol/l ) , severe liver disease ( liver function test &gt; 3 time normal ) unable understand comply protocol give inform consent</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>